Navigation Links
Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
Date:10/30/2008

gh quality people. Most of them are deeply experienced with our lead molecule motexafin gadolinium. In acquiring three promising compounds from Celera, we were very fortunate to inherit a group of experienced scientists that have been closely associated with each of these products from their onset. Our scientists are making great strides in forwarding a product pipeline that is novel, differentiated and full of potential. Without question, these are challenging times and historically those that rise up to face the challenges before them and put solutions into action gain strength in the process and become a good deal more viable than ever before. This is our intention. At Pharmacyclics we are dedicated to advancing our small molecule cancer drug candidates through clinical trials and establishing ourselves as a viable pharmaceutical company bringing real solutions to unmet or underserved patients' needs.

"Our executive team looks forward to providing shareholders, current and prospective, with a full update concerning our progress and plans for the future at our annual meeting scheduled for December 12, 2008."

About Pharmacyclics

Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and immune diseases based on a wide range of targets, pathways and mechanisms. More information about the company, its technology, and products can be found at http://www.pharmacyclics.com. Pharmacyclics(R) and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.

NOTE: Other than statements of historical fact, the statements made in this press release about future plans and timelines for our preclinical studies and clinical trials, progress of and reports of results from preclinical studies and clinical trials, clinic
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
2. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
3. Pharmacyclics Announces It Received Nasdaq Notification
4. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
5. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
6. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
7. United Therapeutics Reports Third Quarter 2008 Financial Results
8. BioMed Realty Trust Reports Third Quarter 2008 Financial Results
9. Varian, Inc. Reports Strong Fourth Quarter 2008 Results
10. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
11. VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... (Nasdaq: DNDN ) announced today that the ... exercised in full their option to purchase an ... public offering price of $24.75 per share. ... of the offering to an aggregate of 17,250,000 ... receive net proceeds from the offering of approximately ...
(Date:12/11/2009)... 11 Ambit Biosciences Corporation announced today the ... D. Anderson Cancer Center of the first patient in ... E fficacy) Phase 2 pivotal trial in ... AC220 is a novel, orally available, potent and ... a FMS-like tyrosine kinase-3 (FLT3) inhibitor. The ACE ...
(Date:12/11/2009)... 11 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ... the appointment of Dr. Alan Warrander to the ... Business Development. ,, "Dr. Warrander will be responsible ... for REOLYSIN(R)," said Dr. Brad Thompson, President and ... the design of a Phase 3 trial examining ...
(Date:12/10/2009)... Calif., Dec. 10 Endologix, Inc. (Nasdaq: ... for aortic disorders, announced today that Dan Lemaitre, ... the Endologix Board of Directors effective December 11, ... and three non-independent directors. ,, Franklin D. Brown, ... to welcome Dan Lemaitre to the Endologix Board ...
Breaking Biology Technology:Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 2Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 3Endologix Appoints Dan Lemaitre to its Board of Directors 2
... increased 40.8% to $11.6 million ... Net Income increased 118.8% to $2.5 ... China Medicine,Corporation (OTC Bulletin Board: CHME) ("China Medicine" ... prescription and over-the-counter,pharmaceuticals, traditional Chinese medicines ("TCM"), nutritional ...
... Tate & Lyle Bio Products today announced that its breakthrough ... a natural ingredient by ECOCERT®, one of the leading international ... ... Loudon, TN August 13, 2008 –- http://www.duponttateandlyle.com/ [DuPont ...
... from the Defense Threat Reduction Agency Will Fund the, Advanced Development ... ... Countermeasure -, CHICAGO, Aug. 13 Advanced Life Sciences,Holdings, ... Agency (DTRA) of the U.S. Department of Defense has awarded the,Company ...
Other Biology Technology:China Medicine Announces Strong Second Quarter 2008 Results 2China Medicine Announces Strong Second Quarter 2008 Results 3China Medicine Announces Strong Second Quarter 2008 Results 4China Medicine Announces Strong Second Quarter 2008 Results 5China Medicine Announces Strong Second Quarter 2008 Results 6China Medicine Announces Strong Second Quarter 2008 Results 7China Medicine Announces Strong Second Quarter 2008 Results 8China Medicine Announces Strong Second Quarter 2008 Results 9China Medicine Announces Strong Second Quarter 2008 Results 10China Medicine Announces Strong Second Quarter 2008 Results 11Zemea Propanediol Approved as a Natural Ingredient by ECOCERT 2Zemea Propanediol Approved as a Natural Ingredient by ECOCERT 3Advanced Life Sciences Awarded U.S. Department of Defense Biodefense Contract Valued at up to $3.8 Million 2Advanced Life Sciences Awarded U.S. Department of Defense Biodefense Contract Valued at up to $3.8 Million 3Advanced Life Sciences Awarded U.S. Department of Defense Biodefense Contract Valued at up to $3.8 Million 4
(Date:12/14/2009)... be transmitted by sneezing, touching, or for Tasmanian ... habit that may have driven the dinosaurs to extinction ... Upcroft, a member of f1000 Biology, highlights the ,paleobiological ... PLoS One. This led them to deduce that a ... bones seen in many tyrannosaurid fossils. , The parasite,s ...
(Date:12/14/2009)... defining feature of humans. That,s until examples of tool use ... array of other mammals. Now, a report in the December ... publication, adds an octopus to the growing list of tool ... trick that the researchers call stilt walking. In it, the ... makes its eight arms rigid, and raises the whole assembly ...
(Date:12/13/2009)... about how a popular class of drugs used ... previously hidden components of chemical communication in the ... the illness, people with schizophrenia also struggle to ... order, difficulties that interfere with their ability to ... Schroeder, a student in the medical scientist training ...
Breaking Biology News(10 mins):Tool use in an invertebrate: The coconut-carrying octopus 2New biosensors reveal workings of anti-psychotic drugs in the living brain 2NYU Langone Medical Center awarded NIH grants totaling 241 560 000 8981 1NYU Langone Medical Center awarded NIH grants totaling 241 560 000 8981 2NYU Langone Medical Center awarded NIH grants totaling 241 560 000 8981 3Give an Hour 28TM 29s Volunteer Mental Health Professionals Provide More Than 241 4 Million in Services to Iraq and Afghanistan Veterans Families a 49927 1Give an Hour 28TM 29s Volunteer Mental Health Professionals Provide More Than 241 4 Million in Services to Iraq and Afghanistan Veterans Families a 49927 2Give an Hour 28TM 29s Volunteer Mental Health Professionals Provide More Than 241 4 Million in Services to Iraq and Afghanistan Veterans Families a 49927 3PHT Names VP to Lead Sales of A Claim Payment Solution for Doctors Hospitals 49924 1PHT Names VP to Lead Sales of A Claim Payment Solution for Doctors Hospitals 49924 2
... new antimicrobial approach can kill bacteria in laboratory experiments ... a key bacterial nutrient, according to research led by ... at the UW, the University of Iowa, and the ... 2 issue of the Journal of Clinical Investigation. ...
... bacterial composition of the oral cavity even in low doses. ... needed to counteract the production of acid between the teeth, ... defend at Umeå University in Sweden on February 23. , ... of the sugar xylose, or wood sugar. Xylitol occurs ...
... light are providing insight into the complexities of the sense ... how the human brain works. , Investigators at Duke University ... a strain of mice whose olfactory brain cells "fire" when ... cells a gene naturally present in green algae that "turns ...
Other Biology News:Trojan horse strategy defeats drug-resistant bacteria 2Xylitol reduces risk of cavities 2Common algae helps illustrate mammalian brain electrical circuitry 2Common algae helps illustrate mammalian brain electrical circuitry 3
Rabbit anti-T-box 6...
TNF-R2 (L-20)...
Assay Kit formatted for flow cytometric detection of levels of phosphorylated histone H2A.X....
... SizeSep 400 Spun Columns, 10. *SizeSep ... cDNAs > 400 base pairs in length. ... Sepharose CL-4B and pre-equilibrated in distilled water containing ... smaller than ~ 400 base pairs. ...
Biology Products: